FY2025 EPS Estimates for Precigen Reduced by HC Wainwright

Precigen, Inc. (NASDAQ:PGEN) – Equities research analysts at HC Wainwright dropped their FY2025 EPS estimates for Precigen in a research report issued on Thursday, May 15th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of ($0.37) for the year, down from their previous forecast of ($0.29). HC Wainwright currently has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Precigen’s Q4 2025 earnings at ($0.04) EPS, FY2026 earnings at ($0.01) EPS, FY2028 earnings at $0.37 EPS and FY2029 earnings at $0.62 EPS.

Precigen (NASDAQ:PGEN) last issued its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $1.34 million during the quarter, compared to analysts’ expectations of $0.50 million. Precigen had a negative net margin of 3,521.68% and a negative return on equity of 123.06%.

Separately, Cantor Fitzgerald reissued an “overweight” rating on shares of Precigen in a report on Thursday. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Precigen Price Performance

PGEN opened at $1.45 on Monday. Precigen has a 1-year low of $0.65 and a 1-year high of $2.17. The stock has a market cap of $427.99 million, a P/E ratio of -2.64 and a beta of 1.82. The stock’s 50 day simple moving average is $1.50 and its 200 day simple moving average is $1.30.

Institutional Trading of Precigen

Large investors have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. lifted its stake in Precigen by 3.8% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 11,276,000 shares of the biotechnology company’s stock valued at $16,801,000 after buying an additional 410,595 shares in the last quarter. Iridian Asset Management LLC CT raised its holdings in shares of Precigen by 38.8% in the fourth quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock worth $5,871,000 after acquiring an additional 1,465,962 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Precigen by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company’s stock worth $3,696,000 after acquiring an additional 53,343 shares during the last quarter. Parkman Healthcare Partners LLC purchased a new stake in shares of Precigen in the first quarter valued at $4,755,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Precigen by 4.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,278,862 shares of the biotechnology company’s stock valued at $1,432,000 after acquiring an additional 56,012 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.